Cigna Investments’s Neurocrine Biosciences NBIX Stock Holding History

Cigna Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,911	Closed	-$279K	–	692
2021 Q3	$279K	Hold	2,911	–	–	0.02%	577
2021 Q2	$283K	Sell	2,911 -350	-11%	-$33.5K	0.02%	595
2021 Q1	$317K	Buy	+3,261	New	+$342K	0.02%	582

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cigna Investments's NBIX Position: Q4 2021 in Review

Cigna Investments sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 2,911 shares — an estimated $279K sold.

Cigna Investments first reported a position in NBIX in Q1 2021 and held it in 3 quarters. The position peaked at $317K in Q1 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

Cigna Investments reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
Cigna Investments sold 2,911 Neurocrine Biosciences shares in Q4 2021, an estimated $279K.
Cigna Investments first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 3 quarters.
Cigna Investments's Neurocrine Biosciences position peaked at $317K in Q1 2021.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Cigna Investments's 13F filing for Q4 2021, filed 14 Feb 2022.